Vaccine & Drug Development
We develop vaccines for TB, malaria, antibiotic-resistant bacteria, coronaviruses, and helminth infections. We focus on biomarker, target, and adjuvant discovery. We also develop dose sparing, smart design strategies, and vaccine enhancements (like mRNA vaccine strategies). In drug development, we aim to identify novel targets through dissecting viral and bacterial replication and host factors at the molecular level, and exploring host-directed therapy.
Ambassadors
- Arjan Lankester
- Frank Staal
- Ramon Arens
- Ton Rabelink
- A van hylckama-Vlieg
- Fijs van Leeuwen
- Martin Giera
- Meindert Lamers
- Mirjam Heemskerk
- Sesmu Arbous
- Manfred Wuhrer
- Noel de Miranda
- Peter van Veelen
- Tessa Buckle
- Wim Jiskoot
- Montse Barcena-Martin
- Martijn van Hemert
- Marjolein Kikkert
- Sebe Myeni
- Leo Visser
- Ron Hokke
- Blandine Franke-Fayard
- Simon Jochems
- Maria Yazdanbakhsh
- Rajagopal Murugan
- Meta Roestenberg
- Angela van Diepen
- Eric Snijder
- Annemieke Geluk
- Tom Ottenhof
- Jeroen Corver
- Mariet Feltkamp
- Simone Joosten
- Anna Roukens
- Hetty Jolink
- Jairo Gooskens
- Wiep Klaas Smits
BSL-3 Research Facility
Biosafety Level 3 (BSL-3) laboratories are designed to safely grow and investigate potentially deadly viral and bacterial pathogens. These laboratories are a crucial component of the defense against (imported) infectious diseases, bio-terrorism, outbreaks, and emerging pandemics. The BSL-3 laboratories and DM-III animal testing facilities provide a controlled working environment where basic and clinical researchers can safely conduct biomedical research on highly pathogenic agents and effectively develop countermeasures, such as diagnostics, vaccines, and medicines.
